Modification of K
Introduction
Voltage-gated K + channels are important determinants of firing patterns in electrically-excitable tissue. 1 Upregulating these currents holds great potential for therapeutic intervention in diseases characterized by hyperexcitability. In skeletal muscle, overexpression of K + channels is reasonably expected to reduce electrical excitability, but the actual result of the exogenous expression of an engineered gene cannot be predicted without experimental observation. In order to study the effects of exogenous K + channel expression on electrical excitability, we overexpressed an engineered K + channel with known kinetic properties and measured the augmentation of outward current using voltage clamp. Electrical excitability was then studied using current clamp to assess the effect on action potential generation.
Herpes simplex virus type 1 (HSV-1) vectors have been used to express transgenes in a variety of post-mitotic cell types, 2 including skeletal muscle cells in vivo and in vitro. [3] [4] [5] [6] An HSV-1-based vector system has been developed using a small amplicon plasmid (4.8 kb) that imposes minimal limitations on the size of the transgene of choice, and that is easy to manipulate using standard molecular biological techniques. 7 In the presence of a replication-deficient helper virus, amplicons can be pack- aged into HSV-1 virions capable of infecting differentiated mammalian cells. 7, 8 Here, we report the effects of overexpression of a voltage-dependent K + channel (eGFP-Kv1.4 fusion protein) in primary cultured rat muscle cells using the helperdependent herpes simplex 1 amplicon system. The transgene ion channel is a fusion protein containing a bioluminescent reporter gene: enhanced green fluorescent protein (eGFP). The resultant increase in total K + current amplitude and its rapid rate of activation leads to an inhibition of excitability by increasing the threshold required for current for firing an action potential. Induction of hyperexcitability in myoballs by the Na + channel toxin anemone toxin II (ATX-II, 1 m) was antagonized by overexpression of Kv1.4. This work provides a promising foundation for the use of transgenic K + channel overexpression as a tool for manipulating cellular excitability.
Results

Expression of pHSVegfp-Kv1.4 in BHK(TK
−
) cells
The eGFP-Kv1.4 fusion protein was made with eGFP linked in frame to the amino-terminal domain of the Shaker-related potassium channel Kv1.4, thus providing a visible marker for channel expression while simultaneously disrupting fast N-type inactivation. 9, 10 The dual functions of the fusion protein as a delayed rectifier K + channel and as a fluorescence marker eGFP were confirmed by expression in HEK293 cells. 9 We subcloned the fusion construct into the herpes simplex 1 amplicon vector, packaged it in virus, and used it to demonstrate suc-cessful infection of cultured cells. Figure 1 shows a schematic map of pHSVegfp-Kv1.4. It contains the herpes origin of replication ORI S , the IE4 herpes promoter, a polyadenylated tail downstream of the egfp-Kv1.4 fusion construct and the HSV 1 packaging sequence (PAC). This PAC sequence directs packaging of the amplicon into the viral particles by the replication-deficient helper virus.
We used BHK(TK − ) cells, which do not contain endogenous voltage-gated K + channels, to confirm expression of functional K + channels following transfection with the pHSVegfp-Kv1.4 viral vector. In Figure 2 , voltage clamp recordings of BHK(TK − ) cells in the wholecell patch clamp configuration are shown. Figure 2a shows the K + currents in an eGFP-Kv1.4-transduced BHK(TK − ) cell that were elicited by a series of voltage steps. As expected, the introduced K + channel activated very quickly ( = 0.4-0.6 ms at +40 mV), and lacked Ntype inactivation. The current traces in Figure 2b show a nontransduced control cell from a virus-exposed culture. No K + current was evident at any voltage step confirming the absence of native K + currents in the BHK cell line. For eGFP-Kv1.4-transduced cells the average maximum current elicited by a membrane potential step to +40 mV was 33.38 ± 1.08 nA (mean ± s.e.m.) at 16-18 h after infection (n = 4). In nontransduced control cells, the current amplitude was 0.30 ± 0.15 nA (mean ± s.e.m., n = 5). As a control for nonspecific effects of viral exposure (including the presence of helper virus and possible effects of overexpression of the eGFP marker), we used the pHSVegfp amplicon, which carries the eGFP gene without Kv1. 4 . Figure 2c depicts an eGFP-transduced cell. In the eGFPtransduced cells, the current amplitude was 0.06 ± 0.01 nA (mean ± s.e.m.; n = 6) at 20-24 h after infection. In Figure 2d the current-voltage relationships for cells transduced with Kv1.4 or GFP alone and the control cells are depicted. As expected, the exogenous Kv1.4 channel activated at membrane potentials more positive than −40 mV and exhibited a strong outward rectification. These data demonstrate that functional eGFPKv1.4 fusion protein channels are expressed from the pHSVegfp-Kv1.4 amplicon introduced by the disarmed herpes virus, and that overexpression of eGFP and viral exposure alone do not induce expression of native ion channels.
Expression of pHSVegfp and pHSVegfp-Kv1.4 in primary skeletal muscle cells Successful gene transfer of the same viral-packaged amplicon into muscle cells was demonstrated with fluorescence imaging using FITC optics. Figure 3 shows fluorescence photomicrographs of primary muscle cultures 25 h after infection with pHSVegfp ( Figure 3a) and pHSVegfp-Kv1.4 (Figure 3b ). Myotubes and fibroblasts could easily be identified by their morphology and were found to be infected at similar ratios. For eGFP alone, labeling was diffuse as is expected for a cytoplasmic protein, whereas labeling for the fusion protein eGFP-Kv1. 4 showed an additional membrane-associated pattern indicating that at least a portion of eGFP-Kv1.4 protein was expressed in the membrane. There were no overt morphological changes and the cells appeared healthy within the 20-32 h duration of the experiments. Exposure for more than 2 days to the experimental or control vector led to visual signs of cytotoxicity believed to be due to effects of the helper virus. 2, 6, 11 Before electrophysiological study, muscle cells were treated with colchicine to produce a rounded shape (myoball) that optimizes voltage clamp properties. Figure 4 shows voltage clamp recordings from myoballs in the whole-cell patch clamp configuration, at days 4-8 in culture. Figure 4a depicts the K + currents evoked by depolarization in a non-transduced control myoball, a pHSVegfp-transduced myoball and a pHSVegfp-Kv1.4-transduced myoball. Recordings were done at 20-30 h after infection in an external solution containing reduced Na + (20 mm) to facilitate voltage control. The currents were elicited by a series of voltage steps in 10 mV increments from a holding potential of −80 mV. The nontransduced and the pHSVegfp-transduced myoballs showed no apparent differences in average amplitude or activation kinetics of the voltage-dependent K + currents, whereas the pHSVegfp-Kv1.4-transduced cell showed a greater than two-fold increase in amplitude, and faster activation ( = 1.0-1.5 ms at +40 mV) as compared with the native current of control cells ( = 6-8 ms at +40 mV). The Kv1.4 current lacked N-type inactivation. Figure 4b depicts the current-voltage relationship for the cells shown in Figure 4a . The eGFP-Kv1.4 channel activated at membrane potentials more positive than −40 mV and showed steep outward rectification. The endogenous K + current in the untreated and eGFP-transduced myoballs also activated at potentials more positive than −40 mV and showed outward rectification although the total current amplitude was smaller. The bar diagram in Figure 4c summarizes the current amplitude at +40 mV in pHSVegfp-Kv1.4-transduced myoballs (19.24 ± 1.85 nA, mean ± s.e.m.; n = 15) versus pHSVegfp-transduced myoballs (7.91 ± 0.90 nA, mean ± s.e.m.; n = 14) and untreated myoballs (7.85 ± 0.87 nA, mean ± s.e.m.; n = 26). The current amplitude increase in eGFP-Kv1.4-infected myoballs was statistically significant (P Ͻ 0.0001, t test) as compared with either control group. In contrast, eGFP- infected and control cells were not significantly different, indicating that eGFP expression alone did not alter the expression of the native K + channels. As depicted in Figure 4d , the additional expression of the fast activating Kv1.4 current effectively counteracted the contribution of Na + channels in eGFP-Kv1.4-transduced myoballs at 28-30 h after infection (Na + current was fully antagonized in four of six myoballs, and strongly reduced in the remaining two myoballs). Lower levels of the Kv1.4 expression that occurred by 20-25 h after infection did not significantly reduce the amplitude of Na + currents (n = 12), but did increase the relative amplitude of the total K + current as compared with that of the Na + currents (K + /Na + -ratio) by a statistically significant amount (P Ͻ 0.01, t test) as seen in Figure 4d .
Current clamp studies were conducted to evaluate the changes in cellular excitability due to the increase in total K + current ( Figure 5 ). Baseline membrane potential was adjusted to −60 to −65 mV, and action potentials were evoked with current pulses (1 s, 1-50 nA) in 20 mm external Na + for myoballs at days 5-8 in culture. Recordings done in 157 mm external Na + gave a comparable firing frequency (data not shown), but problems with the space clamp impaired the parallel voltage clamp analyses in high Na + saline. Figure 5a shows the membrane response of an untreated myoball to current injection (1, 2, 10 and 20 nA) in 20 mm Na + saline. In response to depolarizing current injection, the muscle cells (n = 16) fired a single action potential followed by a rapid repolarization. The cells remained depolarized without additional spiking for the duration of the stimulus, after which the voltage returned to the holding baseline potential. The response of a pHSVefgp-infected myoball was indistinguishable from the untreated controls for the stimulation protocol, as shown in Figure 5b (n = 8) . At 20 h after transduction with pHSVegfp-Kv1.4, the myoballs were activated by a 2 nA stimulus (n = 2; data not shown); however by 28-30 h after infection a suppression of firing was observed. Figure 5c depicts the membrane potential response of a pHSVegfp-Kv1.4-transduced myoball to current injections at 30 h after infection in 20 mm Na + saline. Current injection of 2 nA was not sufficient to induce an action potential and caused only a passive depolarization for the duration of the stimulus. A larger current stimulus (10 nA) elicited a small action potential that did not reach a positive potential. At 20 nA, the current pulse led to a small non-overshooting action potential. At 50 nA, current injection gave rise to an action potential followed by Gene Therapy sustained depolarization. This type of response was seen in eight of eight eGFP-Kv1.4-transduced myoballs tested. Thus, the increased K + current conferred by the Kv1.4 trans-gene raised the threshold for eliciting an action potential. A greater than 10-fold increase in the injected current was necessary to induce an action potential in transduced cells. The total membrane resistance (R M ) was calculated from the magnitude of the passive voltage response to the injected current by plotting the currentvoltage relationship for each cell, fitting the data with a straight line and calculating the R M values from the slope. Untreated control myoballs had a R M of 2.73 ± 0.21 M⍀ (mean ± s.e.m.; n = 10). In contrast, Kv1.4-transduced myoballs had a reduced R M of 1.88 ± 0.28 M⍀ (mean ± s.e.m.; n = 6) consistent with an increase in the density of ion channels in the muscle cell membrane. The difference proved to be statistically significant (P Ͻ 0.05, t test). Figure 6 depicts the K + and Na + currents evoked by depolarization after application of ATX-II (1 m) in a nontransduced control myoball (Figure 6a ), a pHSVegfptransduced myoball ( Figure 6b ) and a pHSVegfp-Kv1.4-transduced myoball (Figure 6c ) at day 4 in culture. The Na + currents in a control myoball in Figure 6a reflected a severely slowed Na + channel inactivation (n = 13) as expected from the known mechanism of action of ATX-II. 12 The eGFP-transduced myoballs at 32 h after infection ( Figure 6b) were indistinguishable from the controls (n = 7). In contrast, in pHSVegfp-Kv1.4-transduced myoballs at 32 h after infection (n = 9) shown in Figure 6c the increased K + current fully antagonized the ATX-II augmented Na + currents, restoring a response equivalent to that seen for Kv1.4-transduced myoballs without ATX-II (see Figure 4a for comparison). Figure 6d depicts the current-voltage relationships of the K + currents for the myoballs shown in Figure 6a , b and c.
Effect of expression of pHSVegfp-Kv1.4 on ATX-IIinduced hyperexcitability in primary skeletal muscle cells
Current clamp studies were conducted to evaluate the changes in cellular excitability due to the application of ATX-II, and the compensatory effect of an increase in total K + current at day 4 in culture ( Figure 7 ). Figure 7a , shows that the stimulation of a nontransduced myoball in ATX-II led to a single broad action potential. Repolarization was substantially slowed as compared with action potentials elicited in untreated control myoballs (see Figure 5a for comparison) as expected from the impairment of Na + channel inactivation. A 2 nA current injection elicited repetitive spiking of broad action potentials and a 10 nA injection elicited a greatly prolonged initial action potential that did not repolarize completely during the duration of the stimulus pulse (n = 10). The responses of pHSVefgp-transduced myoballs (at 32 h after infection) as seen in Figure 7b (n = 7) were comparable with those of the ATX-II-treated controls in Figure 7a . Figure 7c depicts a pHSVegfp-Kv1.4-transduced myoball at 32 h after infection. The 2 nA current injection was not sufficient to induce an action potential, whereas the larger current pulses of 10 nA and 20 nA led to single non-overshooting action potentials (n = 9), characterized by a rapid repolarization phase similar to that seen for Kv1.4-transduced myoballs in the absence of ATX-II treatment (Figure 5c ). The box-plots shown in Figure 7d summarize the durations of action potentials evoked in 
prolonged initial action potential that did not fully repolarize for the duration of the stimulus (n = 10). (b) The responses of a pHSVefgp-transduced myoball (at 32 h after infection) in ATX-II were indistinguishable from those of the control (n = 7). (c) In contrast, for a pHSVegfp-Kv1.4-transduced myoball (at 32 h after infection) in ATX-II a 2 nA current injection was not sufficient to induce any action potential, whereas 10 nA and 20 nA current pulses elicited a single action potential with rapid repolarization phases (n = 9). (d) The box-plots summarize the action potential durations evoked in myoballs (with and without ATX-II treatment) comparing nontransduced myoballs and myoballs transduced with eGFP or Kv1.4. Significant increases in action potential duration as compared with untreated controls were indicated with one asterisk and significant decreases in action potential duration as compared with untreated controls were indicated with two asterisks (P Ͻ 0.02, non-parametric Mann-Whitney test). One data point at 679 ms in the ATX-II-treated control myoballs was occluded from the figure for clarity.
from the initial onset of rapid depolarization, through the repolarization (and after hyperpolarization, if present), until the restoration of the passive response. As expected, ATX-II treatment led to a significant increase in action potential duration in control myoballs and myoballs transduced with eGFP. In contrast, in myoballs transduced with Kv1.4 the action potential duration remained brief, and was significantly different from that of controls and eGFP-transduced myoballs both with and without ATX-II treatment. There was no significant difference in the action potential duration in Kv1.4-transduced myoballs with or without ATX-II, indicating that the overexpression of Kv1.4 completely counteracted the hyperexcitatory effect of ATX-II.
Discussion
To investigate the effects of an augmented K + conductance on electrical excitability in skeletal muscle, we introduced an exogenous voltage-gated K + channel into cultured rat skeletal muscle cells. This is the first report of virally driven expression of a voltage-gated K + channel in skeletal muscle cells. Rat skeletal muscle cells express the voltage-gated K + channels Kv3.4 and Kv1.5 abundantly, and lower levels of Kv1.7.
13-16 Expression of mRNA for Kv1.2 has been shown in skeletal muscle in vivo, 17 but the protein has not been detected in vitro in primary rat muscle cultures. 15 Expression of Kv1.4 has been shown in heart and brain, but not skeletal muscle. 18 The introduction of an exogenous Kv1.4 channel would be expected to change both the total amount of K + current and the characteristics of the current with respect to voltage and time dependence of activation and inactivation.
We used an eGFP-Kv1.4 fusion protein to facilitate the identification of transduced cells for electrophysiological analysis. The addition of the marker protein to the Nterminus changed the kinetic properties of the channel, markedly decreasing fast inactivation. Voltage clamp recordings in the whole-cell configuration demonstrated a greater than two-fold increase in K + current by 20-30 h after transduction with pHSVegfp-Kv1.4. This increase in K + current led to an inhibition of action potential firing, as shown in current clamp recordings. The threshold current necessary to induce an action potential was increased more than 10-fold ( Figure 5 ) at 28-30 h after infection. This result is best explained by the counterbalancing of inward (Na + ) currents with a large fast outward (K + ) current. Voltage clamp recordings (Figure 4 ) demonstrated that the high expression of K + channels leads to a sustained outward current that is rapidly activated at membrane potentials more positive than −40 mV. Data from current clamp recordings suggest that in response to a depolarizing stimulus, Na + channels open in combination with this rapidly activated K + efflux. We suggest that the net ion flow, in sum is electroneutral and the regenerative processes leading to action potential production are hampered. Thus, large currents are necessary to depolarize the membrane sufficiently to induce a partial action potential. This explanation is supported by the fact that the membrane resistance of the myoballs (R M ) is decreased by more then 30% in Kv1.4-transduced myoballs as compared with the controls.
This study demonstrates that virally mediated gene transfer of a voltage-gated K + channel can be used to modify the ability in skeletal muscle cells to respond to an excitatory stimulus. Pending the development of improved strategies for viral delivery to muscle, this finding may set the stage for the development of a gene therapy for muscle diseases resulting from altered electrical excitability such as paramyotonia congenital and hyperkalemic periodic paralysis. In these disorders, missense mutations in a population of voltage-gated Na + channels lead to alterations in the rate of Na + channel inactivation. 12, 19, 20 This is manifested clinically by either myotonic contraction of muscle due to excessive action Gene Therapy potential generation or intermittent flaccid paralysis due to persistent depolarization. ATX-II, which interferes with Na + channel inactivation and thus prolongs action potential duration, reproduces the electrophysiological abnormalities seen in these muscle channelopathies. 12 ATX-II treatment of cultured muscle cells can be used as an in vitro disease model that mimics both the myotonic and paralytic phenotypes. With low amounts of injected current, the delayed Na + channel inactivation induces hyperexcitability and repetitive firing corresponding to the phenotype of myotonic contractions. With larger current injections, ATX-II treatment produces block of activity due to prolonged depolarization following an initial excitation; this response corresponds to the phenotype of flaccid paralysis. The over-expressed K + current induced by the viral vector described in this report is able to override both effects of ATX-II treatment, restoring a firing pattern similar to that of untreated controls.
For potential clinical applications, the excessive damping effects of Kv1.4 overexpression when driven by the strong constitutive promoter used in this study, will need to be limited. In theory, an inducible promoter would allow the determination of a level of K + current that precisely counterbalances the effects of the different mutations of the ␣-subunit of the voltage-gated Na + channel. Alternatively, use of a K + channel trans-gene with slower activation properties might be beneficial in countering abnormal sustained Na + current without decreasing the firing threshold per se for the initial action potential.
The ability to alter the electrical properties of cells using viral vectors expressing voltage-gated K + channels holds promise for the development of gene therapies for a variety of inherited channelopathies.
Materials and methods
Electrophysiology
Virally transformed muscle cells were easily identified using fluorescein (FITC) optics by the expression of the marker eGFP. Electrodes were made with a two-stage puller PP-83 Narishige from Corning (Corning, NY, USA) 7052 glass and fire-polished (1-4 M⍀). All recordings were done at 37°C. The external recording solution contained (in mm): 20 NaCl, 137 N-methyl-D-glucamine aspartate, 3.5 KCl, 2.2 CaCl 2 , 2.2 MgCl 2 , 0.24 NaH 2 PO 4 , 0.44 KH 2 PO 4 , 10 Hepes, 10 glucose, pH 7.3. The intracellular (pipette) solution consisted of (in mm): 100 K-gluconate, 54 KCl, 6 NaCl, 2 MgCl 2 , 10 Hepes, 10 glucose, 6 m CaCl 2 and 8 m EGTA, pH 7.1. The myoballs were pretreated with colchicine (1 m, Sigma, 20 h; St Louis, MO, USA) to prevent spontaneous contractions and improve the space clamp properties by causing the cells to assume a near spherical shape (myoballs). The use of the low external Na + (20 mm) facilitated voltage clamp control of the large myoballs. Anemone toxin (ATX-II; Alomone Labs, Jerusalem, Israel) was added to the external recording solution before the recording. The stock solution (0.5 mm) was made up in external recording solution. The membrane under the cell-attached patch was permeabilized by nystatin (0.1 mg/ml), providing electrical access. The data were collected by an Axopatch 200A amplifier (Axon Instruments, Union Gap, CA, USA), filtered at 2 kHz with a 4 pole lowpass Bessel filter and digitized at a sample interval of 100-200 s.
Gene Therapy
Construction of pHSVegfp-Kv1.4 and pHSVegfp amplicons
The bacterial plasmid (amplicon) was constructed using standard methods of molecular biology. 21 The amplicon was constructed from the plasmid pHSVlac (a gift from Dr A Geller, Boston Children's Hospital, Boston, MA, USA). The lacZ marker gene was excised from the pHSVlac by endonuclease restriction cuts at the HindIII and EcoRI sites. A synthetic polylinker was ligated between the HindIII and EcoRI sites to introduce a set of unique restriction sites: HindIII-AflII-BstXI-XhoI-NheIBclII-ClaI-NsiI-DraIII-EcoRI. The plasmid pHSVegfp was then constructed using the eGFP gene, 22 which was excised from the commercially available GFP plasmid (Clontech, Palo Alto, CA, USA) at the HindIII and AflII sites and ligated into the corresponding sites in the synthetic polylinker region. The final construct was confirmed by DNA sequencing. The egfp-Kv1.4 fusion protein gene was a gift from Dr E Levitan, University of Pittsburgh, Pittburgh, PA, USA. 9 Using BclI and NheI sites, the egfp-Kv1.4 fusion gene was ligated into the synthetic polylinker region. The resulting plasmid, pHSVegfp-Kv1.4 is illustrated in Figure 1 .
Propagation of cell lines and packaging of the viral vector
The E5 cell line (derived from Vero cells) and the d120HSV1 herpes helper virus were the gift of Dr NA DeLuca (University of Pittsburgh). The helper virus contains a deletion of an immediate-early gene (IE4) that is essential for replication. The E5 cells are genetically engineered to allow propagation of the disarmed virus by complementation of the IE4 gene. The E5 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum at a density of 1 × 10 6 cells per 50 ml tissue culture flask, incubated at 37°C with 5% CO 2 and were passaged every 2-3 days. The E5 cells were first transfected with the amplicon plasmids pHSVegfp-Kv1.4 or pHSVegfp using a commercially available cationic lipid according to the manufacturer's protocol (SUPERFECT-reagent; Qiagen, Valencia, CA, USA). The E5 cells were then infected with the disarmed d120 helper virus and repeatedly passaged (two to four times) according to the protocol of Dyer and Tufaro. 23 To prepare the virus, the cells were scraped into the medium, sonicated for 90 s and frozen in liquid N 2 . After thawing and centrifugation for 4 min at 5000 r.p.m. to remove cell debris, the supernatant was then used for transfection of BHK(TK − ) cells or myoballs. The BHK(TK − ) cell line was maintained in DMEM supplemented with 10% fetal bovine serum and 1 m Napyruvate (33°C, 10% CO 2 ). The cells were passaged every 2-3 days.
Primary skeletal muscle cultures
Timed-pregnant Sprague-Dawley rats (Harlan, Indianapolis, IN, USA) were anesthetized by exposure to CO 2 and killed. The preparation of primary cultures was modified from the method described previously. 24 Myocytes were obtained from the forelimbs of fetal rats at embryonic day 20. The tissue was incubated for 20 min at 37°C in 25 ml of 0.25% trypsin-EDTA in phosphatebuffered saline (PBS) without Ca 2+ or Mg 2+ with gentle shaking every 4 min. The digestion was stopped by adding 25 ml of culture medium with serum. After centrifugation at 1000 g for 10 min, the pellet was resuspended in culture medium and the cells were placed in 30-mm plastic dishes (NUNC, Rochester, NY, USA) coated with collagen (0.5 mg/ml; Calbiochem, San Diego, CA, USA). The cells were maintained at 37°C in 5% CO 2 and were fed every 3-4 days. The culture medium was DMEM supplemented with 10% horse serum, 5% fetal bovine serum, 31.6 g/ml penicillin G and 10 g/ml streptomycin sulfate. After day 4 in culture, cytosine-arabinoside (10 m) was added to prevent further growth of fibroblasts.
Imaging
The color images were acquired digitally on a Nikon E800M microscope with a Hamamatsu C5180 camera, using Adobe Photoshop 5.0 software.
